Skip to content
Screener

Kodiak Sciences Inc KOD Liability Related To Sale Of Future Royalties

Liability Related To Sale Of Future Royalties at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+43.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+43.9%
Geron logo
GeronGERN
$20.69M+18.6%
Geron logo
GeronGERN
$20.69M+18.6%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$3.28M-25.7%
Zymeworks logo
ZymeworksZYME
$252.63M

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.84B+556%
Enterprise value$2.73B+592%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept kod:LiabilityRelatedToSaleOfFutureRoyalties.

The source filing: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211951
Line itemMarch 31,2026December 31,2025
Operating lease liability11,66012,063
Total current liabilities49,57345,533
Long-term operating lease liability44,33247,117
Liability related to sale of future royalties100,000100,000
Long-term deposit1,500
Total liabilities193,905194,150
Commitments and contingencies (Note 5)
Stockholders’ equity:

Item 1. Financial Statements (Unaudited).

FAQ

What is Kodiak Sciences Inc's liability related to sale of future royalties?
Kodiak Sciences Inc (KOD) reported liability related to sale of future royalties of $100M in Q1 2026.
How has Kodiak Sciences Inc's liability related to sale of future royalties changed year-over-year?
Kodiak Sciences Inc's liability related to sale of future royalties decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Kodiak Sciences Inc's liability related to sale of future royalties?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's liability related to sale of future royalties has grown at a 0.0% compound annual growth rate (CAGR), from $99.89M to $100M.
What does liability related to sale of future royalties mean?
This represents the financial obligation arising from the upfront monetization of future revenue streams derived from intellectual property or product sales. It reflects a financing arrangement where the company receives immediate capital in exchange for a portion of future royalty payments. Investors monitor this to assess the impact of non-dilutive financing on future cash flows and long-term profitability.

Ask your AI about Kodiak Sciences Inc's liability related to sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude